Business
Cellectar Biosciences, Inc.: This annual report on Form 10-K contains trademarks and service marks of Cellectar Biosciences, Inc.
Net income increased 51.1% to ($21.8M), while Operating cash flow increased 51.4% to ($23.1M).
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue N/AWatch
- Profitability — Net income ($21.8M)Watch
- Cash generation — Free cash flow ($23.1M)Note
- Accounting — No applicable forensic screenNote
- Insiders — 0 buys; 1 sells in 365 daysNote
- Capital — Comparable payout data unavailableNote
Leadership changes
From Cellectar Biosciences, Inc.'s own filings, the day they're filed.
- Andrew Gu · director · appointmenteff. 2026-05-18
Latest filings
- 8-K · Company announcement2026-08-13
- 10-Q · Quarterly report2026-08-13
- 8-K · Company announcement2026-07-10
- DEF 14A · Annual proxy (pay & governance)2026-05-28
- 8-K · Company announcement2026-05-18
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Cellectar Biosciences, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.